KZA 2.47% 79.0¢ kazia therapeutics limited

Novogen rises on “outstanding” drug trial

  1. 3,567 Posts.

    Pharmaceutical company Novogen (NRT) announced today that its NV- 04 cardio-vascular drug program has demonstrated “outstanding” characteristics in its first human clinical trial.

    The objective of the trial was to determine the effects of NV-04 on widening of blood vessels, called dilation which enhances blood flow and can reduce blood pressure.

    According to Dr Jaye Chin-Dusting, head of the Baker Institute Vascular Pharmacology Laboratory, who conducted the study at the Alfred Hospital, in Melbourne, the trial results have demonstrated outstanding potency of the drug and reproducibility in arterial dilation by enhancing the biochemical activities within the blood vessel wall.

    Novogen's research director, professor Alan Husband, said the trial result represented a major milestone in the Novogen cardio-vascular drug program.

    “We have demonstrated that the drug produces effects which are expected to be clinically relevant in improving cardiovascular function,” professor Husband said.

    The NV04 drug program has already demonstrated significant benefits in animal studies, by effectively blocking the development of the types of lesions that are associated with the common forms of heart disease in humans.

    At 1048 AEST Novogen shares were 10c higher to $1.95
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap ! $105.7M
Open High Low Value Volume
80.0¢ 81.0¢ 79.0¢ $48.66K 60.89K

Buyers (Bids)

No. Vol. Price($)
1 8629 78.0¢

Sellers (Offers)

Price($) Vol. No.
79.0¢ 24837 1
View Market Depth
Last trade - 16.10pm 24/05/2022 (20 minute delay) ?
-0.020 ( 1.25 %)
Open High Low Volume
80.0¢ 80.0¢ 79.0¢ 17763
Last updated 15.56pm 24/05/2022 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.